| Identification | Back Directory | [Name]
BenzaMide, 3-Methoxy-N-[3-(1-Methyl-1H-pyrazol-5-yl)-4-[2-(4-Morpholinyl)ethoxy]phenyl]- | [CAS]
887936-68-7 | [Synonyms]
APD791
Temanogrel
3-Methoxy-N-[3-(1-methyl-1H-pyrazol-5-yl)-4-[2-(4-morpholinyl)ethoxy]phenyl]benzamide
BenzaMide, 3-Methoxy-N-[3-(1-Methyl-1H-pyrazol-5-yl)-4-[2-(4-Morpholinyl)ethoxy]phenyl]-
inhibit,Temanogrel,Serotonin Receptor,5-HT Receptor,APD 791,APD-791,Inhibitor,5-hydroxytryptamine Receptor | [Molecular Formula]
C24H28N4O4 | [MDL Number]
MFCD18206792 | [MOL File]
887936-68-7.mol | [Molecular Weight]
436.5 |
| Chemical Properties | Back Directory | [Boiling point ]
556.4±50.0 °C(Predicted) | [density ]
1.24±0.1 g/cm3(Predicted) | [storage temp. ]
Store at -20°C | [solubility ]
DMSO : 125 mg/mL (286.37 mM) | [form ]
Solid | [pka]
12.88±0.70(Predicted) | [color ]
White to off-white |
| Hazard Information | Back Directory | [Uses]
Temanogrel, is a highly selective 5-HT2A receptor antagonist with a Ki of 4.9 nM. Temanogrel also inhibits inositol phosphate accumulation with an IC50 of 5.2 nM. Temanogrel exhibits potent inhibition of serotonin mediated amplification of ADP-stimulated human and dog platelet aggregation (IC50=8.7 and 23.1 nM, respectively | [Definition]
ChEBI: Temanogrel is a member of benzamides. | [in vivo]
There are no differences in heart rate or mean arterial pressure between saline-treated and Temanogrel-treated groups at any time during the experiment (that is, for mean arterial pressure, P=0.508 between groups, and P=0.540 for group-time interaction). In dogs assigned to receive Temanogrel, plasma Temanogrel levels show a rapid and sustained increase, averaging 25.5±4.1, 28.7±4.6 and 31.2±4.5 ng/mL, respectively, at 10 min, 1.25 h and 2.25 h after the start of treatment[3]. | [IC 50]
5-HT2A Receptor: 4.9 nM (Ki) |
|
| Company Name: |
cjbscvictory
|
| Tel: |
13348960310 |
| Website: |
https://www.weikeqi-biotech.com/ |
| Company Name: |
ChemeGen
|
| Tel: |
18818260767 |
| Website: |
https://www.chemegen.com |
|